Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial von Yee, Andrew J, MD, Bensinger, William I, MD, Supko, Jeffrey G, PhD, Voorhees, Peter M, MD, Berdeja, Jesus G, MD, Richardson, Paul G, Prof, Libby, Edward N, MD, Wallace, Ellen E, BA, Birrer, Nicole E, BA, Burke, Jill N, MSN, Tamang, David L, PhD, Yang, Min, PhD, Jones, Simon S, PhD, Wheeler, Catherine A, MD, Markelewicz, Robert J, MD, Raje, Noopur S, Dr

Volltext

Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma von Fonseca, Rafael, Usmani, Saad Z., Mehra, Maneesha, Slavcev, Mary, He, Jianming, Cote, Sarah, Lam, Annette, Ukropec, Jon, Maiese, Eric M., Nair, Sandhya, Potluri, Ravi, Voorhees, Peter M.

Volltext

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study von Trudel, Suzanne, Lendvai, Nikoletta, Popat, Rakesh, Voorhees, Peter M., Reeves, Brandi, Libby, Edward N., Richardson, Paul G., Hoos, Axel, Gupta, Ira, Bragulat, Veronique, He, Zangdong, Opalinska, Joanna B., Cohen, Adam D.

Volltext

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma von Kuhn, Deborah J., Chen, Qing, Voorhees, Peter M., Strader, John S., Shenk, Kevin D., Sun, Congcong M., Demo, Susan D., Bennett, Mark K., van Leeuwen, Fijs W.B., Chanan-Khan, Asher A., Orlowski, Robert Z.

Volltext

The proteasome and proteasome inhibitors in cancer therapy von VOORHEES, Peter M, ORLOWSKI, Robert Z

Volltext

The Proteasome as a Target for Cancer Therapy von VOORHEES, Peter M, DEES, E. Claire, O'NEIL, Bert, ORLOWSKI, Robert Z

Volltext

Targeting the p27 E3 ligase SCFSkp2 results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy von Chen, Qing, Xie, Weilin, Kuhn, Deborah J., Voorhees, Peter M., Lopez-Girona, Antonia, Mendy, Derek, Corral, Laura G., Krenitsky, Veronique Plantevin, Xu, Weiming, Moutouh-de Parseval, Laure, Webb, David R., Mercurio, Frank, Nakayama, Keiichi I., Nakayama, Keiko, Orlowski, Robert Z.

Volltext

Extramedullary multiple myeloma von Bhutani, Manisha, Foureau, David M., Atrash, Shebli, Voorhees, Peter M., Usmani, Saad Z.

Volltext

Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study) von Ehsan, Hamid, Robinson, Myra, Voorhees, Peter M, Cassetta, Kristen, Borden, Shanice, Atrash, Shebli, Bhutani, Manisha, Varga, Cindy, Pineda-Roman, Mauricio, Friend, Reed, Paul, Barry A

Volltext

Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma von Foureau, David, Bhutani, Manisha, Guo, Fei, Rigby, Katherine, Leonidas, Marina, Tjaden, Elise, Fox, Andee, Atrash, Shebli, Paul, Barry, Voorhees, Peter M., Usmani, Saad Z.

Volltext

Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN von Chari, Ajai, Kaufman, Jonathan L., Laubach, Jacob, Sborov, Douglas W., Reeves, Brandi, Rodriguez, Cesar, Silbermann, Rebecca, Costa, Luciano J., Anderson, Larry D., Nathwani, Nitya, Shah, Nina, Bumma, Naresh, Holstein, Sarah A., Costello, Caitlin, Jakubowiak, Andrzej, Wildes, Tanya M., Orlowski, Robert Z., Shain, Kenneth H., Cowan, Andrew J., Pei, Huiling, Cortoos, Annelore, Patel, Sharmila, Lin, Thomas S., Voorhees, Peter M., Usmani, Saad Z., Richardson, Paul G.

Volltext

Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN von Voorhees, Peter M., Rodriguez, Cesar, Reeves, Brandi, Nathwani, Nitya, Costa, Luciano J., Lutska, Yana, Bobba, Padma, Hoehn, Daniela, Pei, Huiling, Ukropec, Jon, Qi, Ming, Lin, Thomas S., Richardson, Paul G.

Volltext

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial von Lonial, Sagar, Prof, Weiss, Brendan M, Prof, Usmani, Saad Z, Prof, Singhal, Seema, Prof, Chari, Ajai, Prof, Bahlis, Nizar J, Prof, Belch, Andrew, Prof, Krishnan, Amrita, Prof, Vescio, Robert A, Prof, Mateos, Maria Victoria, Prof, Mazumder, Amitabha, Prof, Orlowski, Robert Z, Prof, Sutherland, Heather J, Prof, Bladé, Joan, Prof, Scott, Emma C, Prof, Oriol, Albert, MD, Berdeja, Jesus, MD, Gharibo, Mecide, Prof, Stevens, Don A, MD, LeBlanc, Richard, Prof, Sebag, Michael, Prof, Callander, Natalie, Prof, Jakubowiak, Andrzej, Prof, White, Darrell, Prof, de la Rubia, Javier, Prof, Richardson, Paul G, Prof, Lisby, Steen, MD, Feng, Huaibao, PhD, Uhlar, Clarissa M, PhD, Khan, Imran, MD, Ahmadi, Tahamtan, MD, Voorhees, Peter M, Prof

Volltext

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study von Lonial, Sagar, Lee, Hans C, Badros, Ashraf, Trudel, Suzanne, Nooka, Ajay K, Chari, Ajai, Abdallah, Al-Ola, Callander, Natalie, Lendvai, Nikoletta, Sborov, Douglas, Suvannasankha, Attaya, Weisel, Katja, Karlin, Lionel, Libby, Edward, Arnulf, Bertrand, Facon, Thierry, Hulin, Cyrille, Kortüm, K Martin, Rodríguez-Otero, Paula, Usmani, Saad Z, Hari, Parameswaran, Baz, Rachid, Quach, Hang, Moreau, Philippe, Voorhees, Peter M, Gupta, Ira, Hoos, Axel, Zhi, Eric, Baron, January, Piontek, Trisha, Lewis, Eric, Jewell, Roxanne C, Dettman, Elisha J, Popat, Rakesh, Esposti, Simona Degli, Opalinska, Joanna, Richardson, Paul, Cohen, Adam D

Volltext

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma von Usmani, Saad Z., Weiss, Brendan M., Plesner, Torben, Bahlis, Nizar J., Belch, Andrew, Lonial, Sagar, Lokhorst, Henk M., Voorhees, Peter M., Richardson, Paul G., Chari, Ajai, Sasser, A.Kate, Axel, Amy, Feng, Huaibao, Uhlar, Clarissa M., Wang, Jianping, Khan, Imran, Ahmadi, Tahamtan, Nahi, Hareth

Volltext

Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study von Lonial, Sagar, Lee, Hans C., Badros, Ashraf, Trudel, Suzanne, Nooka, Ajay K., Chari, Ajai, Abdallah, Al‐Ola, Callander, Natalie, Sborov, Douglas, Suvannasankha, Attaya, Weisel, Katja, Voorhees, Peter M., Womersley, Lynsey, Baron, January, Piontek, Trisha, Lewis, Eric, Opalinska, Joanna, Gupta, Ira, Cohen, Adam D.

Volltext

Practical Considerations in Managing Relapsed Multiple Myeloma von Agarwal, Amit, Chow, Eric, Bhutani, Manisha, Voorhees, Peter M, Friend, Reed, Usmani, Saad. Z

Volltext

Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial von Trudel, Suzanne, Lendvai, Nikoletta, Popat, Rakesh, Voorhees, Peter M, Reeves, Brandi, Libby, Edward N, Richardson, Paul G, Anderson, Larry D, Sutherland, Heather J, Yong, Kwee, Hoos, Axel, Gorczyca, Michele M, Lahiri, Soumi, He, Zangdong, Austin, Daren J, Opalinska, Joanna B, Cohen, Adam D

Volltext

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial von Voorhees, Peter M., Kaufman, Jonathan L., Laubach, Jacob, Sborov, Douglas W., Reeves, Brandi, Rodriguez, Cesar, Chari, Ajai, Silbermann, Rebecca, Costa, Luciano J., Anderson, Larry D., Nathwani, Nitya, Shah, Nina, Efebera, Yvonne A., Holstein, Sarah A., Costello, Caitlin, Jakubowiak, Andrzej, Wildes, Tanya M., Orlowski, Robert Z., Shain, Kenneth H., Cowan, Andrew J., Murphy, Sean, Lutska, Yana, Pei, Huiling, Ukropec, Jon, Vermeulen, Jessica, de Boer, Carla, Hoehn, Daniela, Lin, Thomas S., Richardson, Paul G.

Volltext

Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma von Voorhees, Peter M, Chen, Qing, Kuhn, Deborah J, Small, George W, Hunsucker, Sally A, Strader, John S, Corringham, Robert E, Zaki, Mohamed H, Nemeth, Jeffrey A, Orlowski, Robert Z

Volltext